Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05742165
Other study ID # 22-01453
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 17, 2023
Est. completion date January 2025

Study information

Verified date May 2024
Source NYU Langone Health
Contact Collin Popp
Phone 646-501-3427
Email Collin.popp@nyulangone.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this pilot feasibility and acceptability, randomized clinical trial will be to examine the effects of two-time restricted eating (TRE) interventions on weight loss maintenance (WLM). This study will be conducted in 40 individuals with non-surgical weight loss of ≥5% initial body weight recruited from the NYU Langone Health Weight Management Program and NY-MOVE! Weight Management Clinic at the Manhattan VA. Measurements will occur at baseline, 4 and 12 weeks. Participants will be randomized with equal allocation to 2 groups: (1) TRE6 or (2) TRE10. The TRE6 will restrict their eating window to 6 hours per day and the TRE10 to 10 hours per day.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 25 Years to 65 Years
Eligibility Inclusion Criteria: - =5% non-surgical weight loss from NYULH-WMP and NY-MOVE! Endocrinology Weight Management Clinic in the last 3 months - BMI between 20.5 - 45 m/kg2 - between the ages 25 to 65 years old - own a smartphone or willing to use a smartphone if provided for self-monitoring - Eating window >12 h per day - <150 mins/wk of physical activity - log at least 2 meals into the smartphone app on =5 days Exclusion Criteria: - <25 years or >65 years of age - Body weight in excess of 400lbs (181.4kg) - pregnant, trying to get pregnant or breastfeeding - previous or planned bariatric surgery - previous or current history of eating disorder - ongoing participation in another weight-management research study - continued participation in a weight loss program other than the proposed study - currently on appetite suppressants - currently following intermittent fasting or skipping meals - eating window <11h 59min/day - perform overnight shift work more than once a week - work that includes travel across one or more time zones - currently on anti-obesity medications (AOMs) such as, GLP-1 analogues (exenatide, tirzepatide, semaglutide, liraglutide) and pancreatic lipase inhibitors (Orlistat/Xenical and Alli) - prescribed medications expected to result in weight loss such as Orlistat, Naltrexone, Bupropion, Lorcaserin, Phentermine, Topiramate, or Liraglutide, and who are unwilling to delay treatment with these medications for the next 3 months - unable or unwilling to provide informed consent - unable to participate meaningfully in the intervention (e.g., uncorrected sight and hearing impairment) - unwilling to accept randomization assignment - unable to log at least 2 meals into the smartphone app on =5 d during the screening period - have type 1 or other conditions that would preclude restricted eating windows - have type 2 diabetes with a HbA1c >7.0% on medications except for metformin alone - narcolepsy - active cancer - organ dysfunction - current steroid use - daytime sleepiness with the Epworth Sleepiness Scale >10 - severe insomnia with a score =15 on the Insomnia Severity Index - >2.5 kg additional weight loss during run-in phase (weight regain is not an exclusion criteria)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Time Restricted Eating (TRE)
TRE involves only consuming food and beverages during a particular consecutive time period - in the case of this study, either 6 hours or 10 hours. Participants will self-select the timing of their first eating occasion of the day, with the provision that their first meal of the day will be consumed within 3 hours of their wake- up time and finished no less than 3 hours prior to bed time. During the fasting period, participants will be encouraged to drink water, and will be permitted to consume zero-calorie beverages. Participants will be instructed to self-monitor all eating occasions using the MyCircadianClock (mCC) smartphone app, which date- and time-stamps all food entries. Participants will also be instructed to self-monitor their body weight daily using a Bluetooth-enabled Renpho scale, which permits remote collection of body weight.

Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (2)

Lead Sponsor Collaborator
NYU Langone Health National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention Rate Percentage of participants who complete all study visits. Measure of feasibility. Up to Week 12
Primary Recruitment Rate Number of individuals who must be approached to enroll one participant in the study. A recruitment funnel will be developed by documenting the total number of eligible patients completing the NYU Langone Health-WMP and NY- MOVE! programs losing =5% of their baseline body weight. Up to Week 12
Primary TRE Experience Questionnaire (TRE-EQ) Score Online questionnaire that includes 5-point scaled items (0=strongly disagree, 5=strongly agree) regarding difficulties encountered with hunger and appetite; eating within the assigned window; coordinating the TRE window with work, school and home demands; and accommodating social connections (e.g., behaviors and preferences of fellow diners). Week 12
Primary Adherence Rate Using data from participant-worn ActiGraphs and on eating patterns, a day will be labeled "adherent" if all eating occasions (food or beverage with caloric value) are measured inside (± 30 minutes) their prescribed eating window. Adherence rate will be calculated by dividing the total number of adherent days by the total number of days with a logged eating occasion. Up to Week 12
Secondary Change from Baseline in Lean Mass Measured using Bioelectrical Impedance Analysis (BIA). Expressed in kilograms. Baseline, Week 12
Secondary Change from Baseline in Fat Mass Measured using BIA. Expressed in kilograms. Baseline, Week 12
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2